» Articles » PMID: 33322110

Assessment of Tissue Distribution and Metabolism of MP1, a Novel Pyrrolomycin, in Mice Using a Validated LC-MS/MS Method

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2020 Dec 16
PMID 33322110
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

MP1 is a novel marinopyrrole analogue with activity in MYCN amplified neuroblastoma cell lines. A rapid, selective, and sensitive liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method was developed and validated for quantitation of MP1 in mouse plasma. Analyte separation was achieved using a Waters Acquity UPLCBEH C18 column (1.7 µm, 100 × 2.1 mm). Mobile phase consisted of 0.1% acetic acid in water (10%) and methanol (90%) at a total flow rate of 0.25 mL/min. The mass spectrometer was operated at unit resolution in the multiple reaction monitoring (MRM) mode, using precursor ion > product ion transitions of 324.10 > 168.30 / for MP1 and 411.95 > 224.15 / for PL-3. The MS/MS response was linear over the concentration range from 0.2-500 ng/mL for MP1, correlation coefficient (r) of 0.988. Precision (% RSD) and accuracy (% bias) were within the acceptable limits as per FDA guidelines. MP1 was stable under storage and laboratory handling conditions. The validated method was successfully applied to assess the solubility, in-vitro metabolism, plasma protein binding, and bio-distribution studies of MP1.

Citing Articles

Development and Validation of an LC-MS/MS Assay for the Quantitation of MO-OH-Nap Tropolone in Mouse Plasma: Application to In Vitro and In Vivo Pharmacokinetic Studies.

Aldhafiri W, Chhonker Y, Ahmed N, Singh S, Haney S, Ford J Molecules. 2024; 29(18).

PMID: 39339419 PMC: 11434026. DOI: 10.3390/molecules29184424.


Coumarin-Based Aldo-Keto Reductase Family 1C (AKR1C) 2 and 3 Inhibitors.

Jonnalagadda S, Duan L, Dow L, Boligala G, Kosmacek E, McCoy K ChemMedChem. 2024; 19(21):e202400081.

PMID: 38976686 PMC: 11537819. DOI: 10.1002/cmdc.202400081.


Marinopyrrole derivative MP1 as a novel anti-cancer agent in group 3 MYC-amplified Medulloblastoma.

Coulter D, Chhonker Y, Kumar D, Kesherwani V, Aldhafiri W, McIntyre E J Exp Clin Cancer Res. 2024; 43(1):18.

PMID: 38200580 PMC: 10782703. DOI: 10.1186/s13046-024-02944-w.


Analogs of Marinopyrrole A Show Enhancement to Observed Potency against Acute Toxoplasma gondii Infection.

Martens M, Liu Y, Sanford A, Wallick A, Warner R, Li R Antimicrob Agents Chemother. 2021; 66(1):e0079421.

PMID: 34662196 PMC: 8765230. DOI: 10.1128/AAC.00794-21.

References
1.
Coughlan D, Gianferante M, Lynch C, Stevens J, Harlan L . Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States. Pediatr Hematol Oncol. 2017; 34(5):320-330. PMC: 6764456. DOI: 10.1080/08880018.2017.1373315. View

2.
Aminzadeh S, Vidali S, Sperl W, Kofler B, Feichtinger R . Energy metabolism in neuroblastoma and Wilms tumor. Transl Pediatr. 2016; 4(1):20-32. PMC: 4729069. DOI: 10.3978/j.issn.2224-4336.2015.01.04. View

3.
Blessy M, Patel R, Prajapati P, Agrawal Y . Development of forced degradation and stability indicating studies of drugs-A review. J Pharm Anal. 2018; 4(3):159-165. PMC: 5761119. DOI: 10.1016/j.jpha.2013.09.003. View

4.
Rickman D, Schulte J, Eilers M . The Expanding World of N-MYC-Driven Tumors. Cancer Discov. 2018; 8(2):150-163. DOI: 10.1158/2159-8290.CD-17-0273. View

5.
Westermark U, Wilhelm M, Frenzel A, Henriksson M . The MYCN oncogene and differentiation in neuroblastoma. Semin Cancer Biol. 2011; 21(4):256-66. DOI: 10.1016/j.semcancer.2011.08.001. View